ResearchMoz

Cancer Symptoms Partnering 2007-2013

Current Partnering
Published Date » 2013-10-08
No. Of Pages » 150
 The Cancer Symptoms Partnering 2007-2013 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies. 
   
 
 
 Trends in solid tumor cancer partnering deals 
 Top solid tumor cancer deals by value 
 Deals listed by company A-Z, industry sector, stage of development, technology type 
 
 
   
 The Solid Tumor Cancer Partnering 2007-2013 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies. 
   
  This report provides details of thelatest cancer symptoms agreements announced in the healthcare sectors, covering:  
   
 
 
 Symptoms 
 Oral mucositis 
 Cancer pain...
TABLE OF CONTENT

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in cancer symptoms partnering
2.1. Introduction
2.2. Cancer symptoms partnering over the years
2.3. Bigpharma cancer symptoms dealmaking activity
2.4. Cancer symptoms partnering by deal type
2.5. Cancer symptoms partnering industry sector
2.6. Cancer symptoms partnering by stage of development
2.7. Cancer symptoms partnering by technology type
2.8. Disclosed financial deal terms for cancer symptoms partnering
2.8.1 Cancer symptoms headline values
2.8.2 Cancer symptoms upfront payments
2.8.3 Cancer symptoms milestone payments
2.8.4 Cancer symptoms royalty rates
 
Chapter 3 – Leading cancer symptoms deals
3.1. Introduction
3.2. Top cancer symptoms deals by value
3.3. Top cancer symptoms deals involving bigpharma
 
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
 
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
 
Appendices
 
Appendix 1 – Deal type definitions
 
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Tables

NA

List of Figures

 
Figure 1: Cancer symptoms partnering since 2007
Figure 2: Bigpharma – top 50 – Cancer symptoms deals 2007 to 2013
Figure 3: Bigpharma cancer symptoms deal frequency – 2007 to 2013
Figure 4: Cancer symptoms partnering by deal type since 2007
Figure 5: Cancer symptoms partnering by industry sector since 2007
Figure 6: Cancer symptoms partnering by stage of development since 2007
Figure 7: Cancer symptoms partnering by technology type since 2007
Figure 8: Cancer symptoms deals with a headline value
Figure 9: Cancer symptoms deals with upfront payment values
Figure 10: Cancer symptoms deals with milestone payments
Figure 11: Cancer symptoms deals with royalty rates, %
Figure 12: Top cancer symptoms deals by value since 2007
Figure 13: Top cancer symptoms deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Upcoming Reports:

Petroleum Coke Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Increasing demand for refined petroleum products and the high price difference between heavy and light crude oil are leading to an increase in demand for heavy crude. Availability of crude as well as the increase in production rates is driving the petroleum coke market.  Petroleum coke is taking over markets like cement and power industry and has also started giving strong competition to coal. Petroleum coke is an excellent and inexpensive product to blend with coal in traditional coal fired boilers. Associated production cost is minimal as it is a by-product of the...
Bio-Based Organic Acids Market - Global Industry Analysis, Size, Share, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Since the last decade, the demand for bio-based organic acids is growing at a steady pace owing to the impact of conventional organic acids on the environment.  In order to cater to this growing demand, more and more organic acid is being produced from renewable sources such as feedstock.  The market for organic acid synthesized from renewable raw material is also driven by the stringent regulations imposed by regulatory bodies of various nations on conventional organic acid producers. Bio-based alternatives for organic acid are eco-friendly and are frugal compared...
Drug Discovery Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Drug discovery is a process of inventing a new medication in the field of pharmaceuticals, biotechnology and pharmacology. Drug discovery is a complex, lengthycomplicated and expensive process. This process is carried out in four stages namely, target identification, target validation, high-speed screening and lead optimization. Though advanced technologies are available, success rate of drug discovery is very low and the time involved is relatively high.  The final stage of drug discovery involves obtaining a patent and running clinical trials. Most of the drugs entering into...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...
Export market in New Zealand driven by innovative and high-value food products
Jul 29, 2014  
Demand for beverages and high value foods in Asia are driving the food and beverage industry in New Zealand. Also there is high demand for dairy products, seafood, meat and processed foods in the Asian economies which fuel the give an export boost to the economy of New Zealand.  Asia has a rapidly growing market for food which in turn is highly beneficial for New Zealand’s export...
Sony plans revival of PlayStation with network services
Jul 29, 2014  
After a nearly USD 10 billion loss over the last six years, Sony Corp has plans of reviving its consumer electronics hero – the PlayStation. Sony will be repositioning the video game console as a center of streamed network services such as social media, music and movies apart from games. The matter is still in its infancy stage of discussion and the plan is to generate revenue from the...